Dimerix Limited (ASX: DXB) - Share Price
Current share price for DXB : $0.220 0.005 (2.22%)+
Dimerix Limited (DXB), an ASX-listed company, is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.
DXB General Information +
| ASX Code | DXB |
| Website | http://www.dimerix.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 132 |
| DXB Share Price | $0.220 |
| Day High | $0.240 |
| Day Low | $0.210 |
| Last Close | $0.225 |
| DXB Share Price Movement | $0.01 ( 2.22% ) |
Prices as at 15:42, 22 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Dimerix Limited (DXB) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Dimerix Limited (DXB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Dimerix Limited (DXB) price-sensitive announcements
DXB - Dimerix Licenses DMX200 to Everest for China and Asia Region
Dimerix Limited has entered into an exclusive license agreement with Everest Medicines for
Dimerix Limited (DXB)
16 Jun 2026 | 10:20 AM
16 Jun 2026 | 10:20 AM
DXB - Trading Halt
Dimerix Limited (ASX: DXB) has requested a trading halt from the Australian Securities Exc
Dimerix Limited (DXB)
15 Jun 2026 | 9:13 AM
15 Jun 2026 | 9:13 AM
DXB - Dimerix Quarterly Activities Report and Appendix 4C
Dimerix Limited has released its quarterly activities report and Appendix 4C for the perio
Dimerix Limited (DXB)
30 Apr 2026 | 9:13 AM
30 Apr 2026 | 9:13 AM
DXB - ACTION3 Statistical Review Complete
Dimerix Limited announced the completion of a blinded statistical review for the ACTION3 P
Dimerix Limited (DXB)
28 Apr 2026 | 9:20 AM
28 Apr 2026 | 9:20 AM
Dimerix Limited (DXB) Recent ASX Announcements
DXB Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$13.25 | -$2.40 | -37.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$17.08 | -$3.80 | -11.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$13.80 | -$4.20 | 21.10% | 0.00 | 0.00 | 0.00% | 0.0% |
DXB Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $51,761M | 0.1108 | -0.1331 | 0.0165 | 11.5895 | 13.3683 | 13.1510 | 4.12% | 3.32% | 3.45% |
| Clinuvel Pharmaceuticals Limited (CUV) | $501M | 0.0287 | 0.0233 | 0.0942 | 13.8301 | 13.5157 | 12.3523 | 0.50% | 0.73% | 1.18% |
| Dimerix Limited (DXB) | $126M | -0.3740 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,667M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,860M | -1.3893 | 0.0000 | -0.1292 | 0.0000 | 268.1648 | 307.9570 | 0.00% | 0.00% | 0.00% |
DXB Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 10.04 | 0.00 |
| Market | 0.29 | 13.20 | 1.17 | 0.67 |
| Sector | 0.43 | 26.00 | 2.55 | 2.41 |
DXB Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Nina Webster | Chief Executive Officer, Managing Director | 27 Aug 2018 |
| Mr Mark P Diamond | Non-Executive Chairman, Non-Executive Director | 1 Dec 2023 |
| Mr Hugh Alsop | Non-Executive Director | 1 May 2017 |
| Dr Sonia Maria Poli | Non-Executive Director | 3 Jul 2015 |
| Mr Clinton Snow | Non-Executive Director | 1 May 2023 |
Dimerix Limited (DXB) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Dec 2025 | SNOW, Clinton | Issued | Options | 300,000 | $0.321 | $96,300.000 |
| 12 Dec 2025 | ALSOP, Hugh | Issued | Options | 300,000 | $0.321 | $96,300.000 |
| 12 Dec 2025 | WEBSTER, Nina | Issued | Options | 2,500,000 | $0.437 | $1,093,500.000 |
See all changes in directors' interest & trades for Dimerix Limited (DXB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
DXB Management
| Name | Position |
|---|---|
| Dr Robert Shepherd | Chief Commercialisation Officer |
| Michael (Mike) Tonroe | Chief Financial Officer,Company Secretary |
| Dr David Fuller | Chief Medical Officer |
DXB Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Dimerix Limited (DXB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 40,018,964 (6.67%) | Mr Peter Meurs |
| 36,865,281 (6.14%) | Skiptan Pty Ltd ATFT P&M Meurs Family Trust |
DXB Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 27 August 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
